Lisa Bennett is a seasoned professional in the pharmaceutical and medical device industry, with a diverse background spanning from R&D to aseptic processing and sterile medicine manufacture to Quality Management Systems and auditing.

Being passionate about collaboration and knowledge sharing across industry, she volunteers with the Parenteral Drug Association (PDA) and is an active member of the PDA Board of Directors, PDA Regulatory Affairs and Quality Advisory Board (RAQAB) and the PDA Australia Chapter Board. Through these roles she contributes to the PDA mission of advancing pharma manufacturing science and regulation so members can better serve patients.

Known for her commitment to quality and attention to detail, Lisa actively engages with industry stakeholders, collaborates on knowledge sharing opportunities such as conferences, workshops, training and publications, and stays abreast of medicine regulators' expectations. 

Beyond her work with PDA, Lisa has held roles in industry supporting the manufacture of biologicals and cell and gene therapies, and her consultancy and training services include various aspects of human and animal pharmaceutical manufacturing, including quality assurance, aseptic processing and good manufacturing practices.

Justine is Chief Executive Officer at CBE Pure Solutions, Contract Manufacturing and testing services in Melbourne.

Justine is also a former Director of CBE, Centre of Biopharmaceutical Excellence, leading consulting firm providing service to Biopharmaceutical Industry in the areas of strategy, operations, compliance, training, regulatory & clinical support and facility design.

As a senior leader with extensive technical and management experience in Quality and Manufacturing in the Pharmaceutical, Biotechnology and Medical Device industries, Justine has worked on assignments in USA, Europe and Asia over a career span over 25 years.

Formally, a Senior Director of Quality Operations for ANZ and India at Hospira Corp. Pty Ltd and Pfizer Corp. Pty Ltd, Justine has had responsibility for providing technical, operational and strategic leadership to ensure site compliance in accordance with US FDA, EU-TGA-PIC/s regulations and local and international standards. Justine has particular expertise in Microbiology, environmental monitoring and aseptic processing compliance.

Justine is a registered auditor for the Australian Pesticides and Veterinary Manufacturing Authority (APVMA) on behalf of the Australian government, a technical assessor for National Association of Authorities (NATA) and current President for the PDA, Australian chapter

Mylinh is currently the Senior Lab Manager within the CSIRO's National Vaccine and Therapeutics Laboratory with over 20 years of experience working in both the academic research environment and the Biotech industry (Murex Biotech, Abbott Laboratory). Mylinh gained her Ph.D at the University of Melbourne (Department of Pharmacology), she is also an Alexander Von Humboldt Fellow, and a Research Fellow at the William Harvey Research Institution (University of London, UK), and an honorary senior lecturer in immunopharmacology. Mylinh areas of expertise and interests include large scale manufacture of monoclonal and recombinant protein using single use bioreactor, she also spent several years within the Supply Chain Management team at Murex Biotech and had first-hand experience with Lean Six Sigma for process improvement. 

She later moved to CSIRO and helped to establish the CSIRO Tissue Culture Facility and more recently was involved in the design/ establishment/ qualification of a new manufacture clean room suites, CSIRO's new National Vaccine and Therapeutics Laboratory. Mylinh current interests are Environmental Monitoring; Contamination Control Strategy; Equipment and Process Validations and Phase Appropriate Manufacturing.    

Mylinh is a committee member of the Parenteral Drug Association (PDA), Australian Chapter since 2018.

Dr. Peter Qiu is the External Advocacy Lead for Asia Pacific at Roche Genentech with over 13 years of experience working with the US FDA. He was the Division Director in the Division of Biotechnology Manufacturing, Office of Pharmaceutical Manufacturing Assessment, CDER. He led the assessment of manufacturing processes, facilities, and microbiological control for CDER's Biologics License Application review and inspection program.

Dr. Qiu has extensive knowledge in microbial controls and sterility assurance assessment as well as in pre-license and pre-approval inspections for biotech products.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences.

Dr. Hue Kwon has been advising and consulting internationally as a senior advisor consultant on GxP quality maturity, remediation and digital transformation for various pharma/biotech organizations. She has over 20 years of experience in GxP quality and regulatory strategies from working within the biopharmaceutical industry including being a Vice President for Samsung Bioepis Quality Team providing GxP quality and compliance oversight for the end-to-end drug development and lifecycle and being the Head of Business Management and Head of Quality and Compliance as a member of a senior management team at Roche and Novartis for leading international GxP capability building and interaction with foreign regulatory agencies to influence in the decision making and building consensus.

Until December 2010, she served at US FDA for about 9 years on the development of regulatory guidance, emerging regulatory strategy and review and data integrity inspections.